| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, …
Over the last 12 months, insiders at Jasper Therapeutics, Inc. have bought $0 and sold $0 worth of Jasper Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Jasper Therapeutics, Inc. have bought $5.36M and sold $96,384 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 41,000 shares for transaction amount of $99,630 was made by Shizuru Judith Anne (director) on 2025‑09‑22.
| 2025-09-22 | Shizuru Judith Anne | director | 41,000 0.2413% | $2.43 | $99,630 | -55.12% | ||
| 2025-09-22 | MARTELL RON | President and CEO | 41,000 0.2413% | $2.43 | $99,630 | -55.12% | ||
| 2025-09-22 | WIGGANS THOMAS G | director | 41,000 0.2413% | $2.43 | $99,630 | -55.12% | ||
| 2025-09-22 | Lucas Svetlana | director | 20,000 0.1177% | $2.43 | $48,600 | -55.12% | ||
| 2024-12-12 | Sale | Mahal Jeetinder Singh | Chief Operating Officer | 900 0.0065% | $22.11 | $19,899 | -79.34% | |
| 2024-09-12 | Sale | Mahal Jeetinder Singh | Chief Operating Officer | 900 0.0245% | $21.23 | $19,104 | -73.96% | |
| 2024-06-12 | Sale | Mahal Jeetinder Singh | Chief Operating Officer | 900 0.0279% | $24.16 | $21,740 | -26.98% | |
| 2024-03-12 | Sale | Mahal Jeetinder Singh | Chief Operating Officer | 900 0.0306% | $26.44 | $23,792 | -18.58% | |
| 2024-02-08 | Velan Capital Investment Management LP | 10 percent owner | 350,000 5.8207% | $12.95 | $4.53M | +23.01% | ||
| 2024-02-08 | Carlyle Group Inc. | Former 10% Owner | 190,000 3.1598% | $12.95 | $2.46M | +23.01% | ||
| 2023-11-28 | WIGGANS THOMAS G | director | 10,000 0.0091% | $0.65 | $6,486 | +219.69% | ||
| 2023-11-21 | WIGGANS THOMAS G | director | 10,000 0.009% | $0.64 | $6,383 | +221.76% | ||
| 2023-11-20 | WIGGANS THOMAS G | director | 10,000 0.0089% | $0.63 | $6,309 | +219.97% | ||
| 2023-11-17 | WIGGANS THOMAS G | director | 10,000 0.0087% | $0.60 | $5,966 | +224.56% | ||
| 2023-11-16 | WIGGANS THOMAS G | director | 10,000 0.009% | $0.60 | $5,965 | +233.33% | ||
| 2023-10-13 | Sale | Lis William | director | 7,965 0.007% | $0.85 | $6,777 | +122.53% | |
| 2023-06-13 | Sale | Mahal Jeetinder Singh | See Remarks | 9,000 0.0098% | $1.66 | $14,915 | -20.35% | |
| 2023-04-14 | Sale | French Anna Louise | director | 7,000 0.0081% | $1.48 | $10,360 | -8.28% | |
| 2023-04-13 | Sale | Lis William | director | 8,500 0.0093% | $1.44 | $12,240 | -11.33% | |
| 2023-04-13 | Sale | EMSTER KURT VON | director | 9,075 0.0102% | $1.49 | $13,524 | -11.33% |
| Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 8519648 25.6041% | $4.09M | 1 | 0 | <0.0001% |
| Velan Capital Investment Management LP | 10 percent owner | 1188500 3.5718% | $570,480.00 | 1 | 0 | |
| Carlyle Group Inc. | Former 10% Owner | 1066189 3.2042% | $511,770.72 | 2 | 0 | <0.0001% |
| Shizuru Judith Anne | director | 156901 0.4715% | $75,312.48 | 1 | 0 | <0.0001% |
| MARTELL RON | President and CEO | 74118 0.2227% | $35,576.64 | 1 | 0 | <0.0001% |
| WIGGANS THOMAS G | director | 41000 0.1232% | $19,680.00 | 6 | 0 | +177.37% |
| Lucas Svetlana | director | 20000 0.0601% | $9,600.00 | 1 | 0 | <0.0001% |
$18,815,063 | 62 | -6.45% | $13.7M | |
$1,993,425 | 46 | -21.91% | $13.95M | |
$30,257,839 | 29 | -15.72% | $12M | |
$555,628 | 21 | 43.52% | $12.04M | |
$37,200,153 | 21 | -47.67% | $12.66M |
| Increased Positions | 33 | +49.25% | 6M | +28.86% |
| Decreased Positions | 28 | -41.79% | 6M | -28.94% |
| New Positions | 11 | New | 524,700 | New |
| Sold Out Positions | 16 | Sold Out | 4M | Sold Out |
| Total Postitions | 72 | +7.46% | 20M | -0.08% |
| Velan Capital Investment Management Lp | $4,910.00 | 9.53% | 2.67M | +1M | +86.1% | 2025-09-30 |
| Soleus Capital Management, L.P. | $2,750.00 | 5.34% | 1.49M | 0 | 0% | 2025-09-30 |
| Acorn Capital Advisors, Llc | $2,544.00 | 4.94% | 1.38M | +1M | New | 2025-09-30 |
| Kingdon Capital Management, L.L.C. | $2,438.00 | 4.73% | 1.32M | +640,138 | +93.49% | 2025-09-30 |
| Rock Springs Capital Management Lp | $2,025.00 | 3.93% | 1.1M | +555,555 | +101.91% | 2025-09-30 |
| Carlyle Group Inc. | $1,962.00 | 3.81% | 1.07M | 0 | 0% | 2025-09-30 |
| Woodline Partners Lp | $1,913.00 | 3.71% | 1.04M | +1M | New | 2025-09-30 |
| Vanguard Group Inc | $1,900.00 | 3.69% | 1.03M | +408,245 | +65.36% | 2025-09-30 |
| Propel Bio Management, Llc | $1,893.00 | 3.67% | 1.03M | +1M | New | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $1,893.00 | 3.67% | 1.03M | +325,158 | +46.21% | 2025-09-30 |